Open Payments

ZEID K KAYALI

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine
Where
RIALTO, CA
NPI
1396777538
Received
$230,219 in 755 records, 2019 to 2025 ($219,776 general, $10,442 research)
As principal investigator
$14,009,469 of research payments to others in 2,082 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment132$50,660
2024General payment120$21,214
2024Research payment1$3,200
2023General payment141$24,313
2022General payment97$22,515
2022Research payment4$1,977
2021General payment89$16,854
2020General payment54$14,762
2020Research payment2$761
2019General payment114$69,456
2019Research payment1$4,504

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.157$68,6942019–2025
ABBVIE INC.253$66,8112019–2025
Madrigal Pharmaceuticals53$50,1082024–2025
Exelixis Inc.22$23,4392019
Eli Lilly and Company5$6,0792019–2022
PFIZER INC.32$5,5152019–2025
Intercept Pharmaceuticals, Inc.35$4,8222019–2025
Salix Pharmaceuticals, a division of Bausch Health US, LLC92$1,1922019–2025
Astellas Pharma Inc2$1,1632022
Celgene Corporation36$5272021–2024
GENZYME CORPORATION14$3902022–2025
Shionogi Inc6$3532019
Ipsen Biopharmaceuticals, Inc2$2272025
Eisai Inc.7$1322019–2022
ALBIREO PHARMA, INC.5$942022–2024
Phathom Pharmaceuticals, Inc.2$622024–2025
Dova Pharmaceuticals3$612019
Merck Sharp & Dohme LLC4$602021–2023
Ardelyx, Inc.4$582023–2024
Regeneron Healthcare Solutions, Inc.2$562023
Mallinckrodt Hospital Products Inc.2$552020–2025
Takeda Pharmaceuticals U.S.A., Inc.2$512024–2025
E.R. Squibb & Sons, L.L.C.3$422019–2020
Mirum Pharmaceuticals, Inc.2$372024
CapsoVision, Inc.2$342025
ORPHALAN INC1$282024
Alnylam Pharmaceuticals Inc.1$262025
Novo Nordisk Inc1$242025
Dynavax Technologies Corporation2$212019
W. L. Gore & Associates, Inc.1$152023
RedHill Biopharma Inc.1$132023
Exact Sciences Corporation1$132023

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v57$182,671
Food and Beverage633$16,517
Research payment8$10,442
Travel and Lodging47$9,993
Honoraria3$7,190
Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing1$3,200
Consulting Fee1$150
Education5$54

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-17ABBVIE INC.$11Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-12-13Gilead Sciences, Inc.$25Food and BeverageIn-kind items and services2025
2025-12-12Madrigal Pharmaceuticals$5Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-11Madrigal Pharmaceuticals$1,763Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-12-11Madrigal Pharmaceuticals$22Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-09Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-12-09Madrigal Pharmaceuticals$128Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-08ABBVIE INC.$9Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-12-03Madrigal Pharmaceuticals$32Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-03Madrigal Pharmaceuticals$3Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-02Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2025
2025-12-01ABBVIE INC.$29Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-11-19Salix Pharmaceuticals, a division of Bausch Health US, LLC$16Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-11-18ABBVIE INC.$33Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-11-17Madrigal Pharmaceuticals$42Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-11-12Alnylam Pharmaceuticals Inc.$26Food and BeverageIn-kind items and servicesGIVLAARI Drug, Genetic Disease2025
2025-11-11Gilead Sciences, Inc.$3,940Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-11-10Novo Nordisk Inc$24Food and BeverageIn-kind items and servicesWegovy Drug, Obesity2025
2025-11-05Madrigal Pharmaceuticals$38Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-11-03Gilead Sciences, Inc.$16Food and BeverageIn-kind items and services2025
2025-11-02Phathom Pharmaceuticals, Inc.$34Food and BeverageCash or cash equivalentVOQUEZNA Drug, Gastroenterology2025
2025-10-30ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-29PFIZER INC.$13Food and BeverageIn-kind items and servicesVELSIPITY Drug, INFLAMMATION;PAIN2025
2025-10-28Gilead Sciences, Inc.$124Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-10-22ABBVIE INC.$21Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-10-21Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-10-21Madrigal Pharmaceuticals$145Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-10-16ABBVIE INC.$33Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-15Ipsen Biopharmaceuticals, Inc$194Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-10-15Gilead Sciences, Inc.$6Food and BeverageIn-kind items and services2025
2025-10-09ABBVIE INC.$17Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-02ABBVIE INC.$30Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-09-30GENZYME CORPORATION$35Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-09-24Madrigal Pharmaceuticals$44Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-09-22Gilead Sciences, Inc.$144Food and BeverageIn-kind items and services2025
2025-09-22ABBVIE INC.$28Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-09-22Intercept Pharmaceuticals, Inc.$14Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2025
2025-09-16Salix Pharmaceuticals, a division of Bausch Health US, LLC$15Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-09-16Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-09-03Gilead Sciences, Inc.$6Food and BeverageIn-kind items and services2025
2025-08-27Madrigal Pharmaceuticals$44Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-08-26Gilead Sciences, Inc.$3,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-08-26ABBVIE INC.$15Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-08-20Gilead Sciences, Inc.$13Food and BeverageIn-kind items and services2025
2025-08-19Gilead Sciences, Inc.$121Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-08-19Gilead Sciences, Inc.$7Food and BeverageIn-kind items and services2025
2025-08-18Intercept Pharmaceuticals, Inc.$27Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2025
2025-08-14ABBVIE INC.$33Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-08-13Madrigal Pharmaceuticals$2,115Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-08-13ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-08-12Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-08-12Madrigal Pharmaceuticals$140Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-08-11Madrigal Pharmaceuticals$50Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-08-09Gilead Sciences, Inc.$27Food and BeverageIn-kind items and services2025
2025-08-08Gilead Sciences, Inc.$149Food and BeverageIn-kind items and services2025
2025-08-07ABBVIE INC.$6Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-26Madrigal Pharmaceuticals$27Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-07-24ABBVIE INC.$15Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-21Salix Pharmaceuticals, a division of Bausch Health US, LLC$19Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-07-21Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-07-15ABBVIE INC.$32Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-07-12Gilead Sciences, Inc.$29Food and BeverageIn-kind items and services2025
2025-07-08ABBVIE INC.$26Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-07-03Takeda Pharmaceuticals U.S.A., Inc.$38Food and BeverageIn-kind items and servicesENTYVIO Biological, INTERNAL MEDICINE2025
2025-06-24Madrigal Pharmaceuticals$49Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-06-24ABBVIE INC.$21Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-06-20ABBVIE INC.$15Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-06-16Intercept Pharmaceuticals, Inc.$19Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2025
2025-06-14Gilead Sciences, Inc.$29Food and BeverageIn-kind items and services2025
2025-06-09GENZYME CORPORATION$39Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-05-30ABBVIE INC.$17Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-05-29Salix Pharmaceuticals, a division of Bausch Health US, LLC$16Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-05-28ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-05-21PFIZER INC.$20Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2025
2025-05-20Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-20Madrigal Pharmaceuticals$121Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-19Ipsen Biopharmaceuticals, Inc$33Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2025
2025-05-13Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-13Madrigal Pharmaceuticals$129Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-12Intercept Pharmaceuticals, Inc.$20Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2025
2025-05-08Madrigal Pharmaceuticals$5,993Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-08Madrigal Pharmaceuticals$330Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-08Madrigal Pharmaceuticals$203Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-08Madrigal Pharmaceuticals$141Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-08Madrigal Pharmaceuticals$45Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-08Madrigal Pharmaceuticals$20Food and BeverageCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-07GENZYME CORPORATION$34Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-04-30CapsoVision, Inc.$18Food and BeverageCash or cash equivalentCapsoCam Plus Device, Gastroenterology2025
2025-04-28Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-04-24Madrigal Pharmaceuticals$41Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-21Mallinckrodt Hospital Products Inc.$29Food and BeverageIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2025
2025-04-17ABBVIE INC.$11Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-04-16ABBVIE INC.$14Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-04-16ABBVIE INC.$4Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-04-16Gilead Sciences, Inc.$2Food and BeverageIn-kind items and services2025
2025-04-15CapsoVision, Inc.$16Food and BeverageCash or cash equivalentCapsoCam Plus Device, Gastroenterology2025
2025-04-10ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-04-09PFIZER INC.$22Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2025
2025-04-08ABBVIE INC.$6Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-04-02Madrigal Pharmaceuticals$39Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-01ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-03-31ABBVIE INC.$21Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-03-29Gilead Sciences, Inc.$22Food and BeverageIn-kind items and services2025
2025-03-28Salix Pharmaceuticals, a division of Bausch Health US, LLC$11Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-03-26Gilead Sciences, Inc.$26Food and BeverageIn-kind items and services2025
2025-03-13ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-03-12Madrigal Pharmaceuticals$2,820Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-03-11Salix Pharmaceuticals, a division of Bausch Health US, LLC$11Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-03-05ABBVIE INC.$8Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-28Madrigal Pharmaceuticals$9Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-02-27Madrigal Pharmaceuticals$1,763Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-02-27ABBVIE INC.$14Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-26GENZYME CORPORATION$28Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-02-21Madrigal Pharmaceuticals$7Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-02-19Madrigal Pharmaceuticals$4,935Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-02-19Madrigal Pharmaceuticals$274Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-02-19Madrigal Pharmaceuticals$167Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-02-19Madrigal Pharmaceuticals$121Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-02-18ABBVIE INC.$19Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-02-17ABBVIE INC.$4Food and BeverageIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGY2025
2025-02-10Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2025-02-04ABBVIE INC.$23Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-04Gilead Sciences, Inc.$20Food and BeverageIn-kind items and services2025
2025-02-01ABBVIE INC.$28Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-01-27Madrigal Pharmaceuticals$48Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-01-27ABBVIE INC.$3Food and BeverageIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGY2025
2025-01-24ABBVIE INC.$14Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-01-22Intercept Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2025
2025-01-22Gilead Sciences, Inc.$20Food and BeverageIn-kind items and services2025
2025-01-16ABBVIE INC.$10Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-01-09ABBVIE INC.$31Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-01-02Salix Pharmaceuticals, a division of Bausch Health US, LLC$12Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2025
2024-12-23Salix Pharmaceuticals, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-12-23Salix Pharmaceuticals, a division of Bausch Health US, LLC$12Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-12-23Salix Pharmaceuticals, a division of Bausch Health US, LLC$1Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-12-16Madrigal Pharmaceuticals$28Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-12-11Intercept Pharmaceuticals, Inc.$29Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2024
2024-12-10ABBVIE INC.$30Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-12-05ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-12-04ALBIREO PHARMA, INC.$22Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2024
2024-12-02ABBVIE INC.$20Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-11-26Madrigal Pharmaceuticals$48Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-11-21ABBVIE INC.$13Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-11-19GENZYME CORPORATION$33Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2024
2024-11-14ABBVIE INC.$30Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-11-06ABBVIE INC.$22Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-11-04Madrigal Pharmaceuticals$46Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-10-23ABBVIE INC.$20Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-10-16Madrigal Pharmaceuticals$3,173Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-10-16Madrigal Pharmaceuticals$144Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-10-16ABBVIE INC.$12Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-10-15ABBVIE INC.$31Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-10-14Madrigal Pharmaceuticals$14Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-10-10PFIZER INC.$19Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2024
2024-10-09Gilead Sciences, Inc.$14Food and BeverageIn-kind items and services2024
2024-10-04Celgene Corporation$11Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-09-26PFIZER INC.$3,200Research paymentIn-kind items and servicesPF07055341 CLINICAL PUBLICATION PROGRAM2024
2024-09-25ABBVIE INC.$11Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-09-24Madrigal Pharmaceuticals$50Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-09-19ABBVIE INC.$30Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-09-18Mirum Pharmaceuticals, Inc.$20Food and BeverageIn-kind items and servicesLivmarli Drug, Alagille syndrome2024
2024-09-14Gilead Sciences, Inc.$34Food and BeverageIn-kind items and services2024
2024-09-12Madrigal Pharmaceuticals$4,583Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$329Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$250Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$142Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$24Travel and LodgingCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$20Food and BeverageCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-10Gilead Sciences, Inc.$60Travel and LodgingIn-kind items and servicesEpclusa Drug, HCV2024
2024-09-10GENZYME CORPORATION$30Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2024
2024-09-10ABBVIE INC.$16Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-09-04Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-09-03Ardelyx, Inc.$17Food and BeverageIn-kind items and servicesIBSRELA Drug, GASTROENTEROLOGY2024
2024-08-29Celgene Corporation$20Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-08-23Celgene Corporation$8Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-08-22Gilead Sciences, Inc.$3,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2024
2024-08-20Gilead Sciences, Inc.$121Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2024
2024-08-20ALBIREO PHARMA, INC.$16Food and BeverageIn-kind items and servicesIQIRVO Drug, Rare Disease2024
2024-08-20Salix Pharmaceuticals, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-08-19Salix Pharmaceuticals, a division of Bausch Health US, LLC$16Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-08-16Celgene Corporation$18Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-08-15ABBVIE INC.$19Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-08-09Gilead Sciences, Inc.$26Food and BeverageIn-kind items and services2024
2024-08-08Gilead Sciences, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-08-07Celgene Corporation$12Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2024
2024-08-03ABBVIE INC.$6Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-07-29Ardelyx, Inc.$14Food and BeverageIn-kind items and servicesIBSRELA Drug, GASTROENTEROLOGY2024
2024-07-29Salix Pharmaceuticals, a division of Bausch Health US, LLC$8Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-07-29Salix Pharmaceuticals, a division of Bausch Health US, LLC$6Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-07-25ABBVIE INC.$14Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-07-18ABBVIE INC.$16Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-07-17ABBVIE INC.$2,875Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2024
2024-07-10ABBVIE INC.$22Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-07-10Salix Pharmaceuticals, a division of Bausch Health US, LLC$21Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2024
2024-07-08ABBVIE INC.$32Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-07-03GENZYME CORPORATION$20Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2024
2024-07-02ABBVIE INC.$7Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-07-01Intercept Pharmaceuticals, Inc.$20Food and BeverageIn-kind items and servicesOCALIVA Drug, Hepatology / Gastroenterology2024
2024-07-01ABBVIE INC.$4Food and BeverageIn-kind items and servicesCREON Drug, ENDOCRINOLOGY2024
2024-06-28ORPHALAN INC$28Food and BeverageIn-kind items and servicesCUVRIOR Drug, Hepatology2024

The latest 200 records of 755.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31Merck Sharp & Dohme LLCInland Empire Clinical Trials, LLC$31,605A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficac2025
2025-12-22Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$2,278A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$479An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19Genentech, Inc.INLAND EMPIRE LIVER FOUNDATION$72,997Giredestrant HI2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-19X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,000A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$146A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,950A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$8,800A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$146A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$19A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-12-17Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,500A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$877A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$3,238A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$860A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$860A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$9,514A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$4,869A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$877A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-19Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$353A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-19Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$39A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-14Regeneron Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$1,241A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-11-07Regeneron Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$1,241A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$479An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$479An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$479An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,369An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$3,665An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,916An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$6,470An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$10,824An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,882An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$479An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$2,242An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-11-03X4 Pharmaceuticals, Inc.INLAND EMPIRE CLINICAL TRIALS LLC$7,051An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M2025
2025-10-31Genentech, Inc.INLAND EMPIRE LIVER FOUNDATION$14,656Giredestrant HI2025
2025-10-30Eli Lilly and CompanyMAINE CENTER FOR CANCER MEDICINE &$54,597A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR2025
2025-10-29Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$650A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-29Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$3,900A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-29Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$250A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-29Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$3,850A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,942A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$3,818A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$23A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$34A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$219A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$4,869A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$39A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-27Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$474A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of2025
2025-10-22Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,000A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-22Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,500A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-22Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,950A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-22Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$8,800A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,942A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,942A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,942A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$4,869A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$2,587A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHINLAND EMPIRE LIVER FOUNDATION$1,942A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Bernardino CountyRialto city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Rialto, CA, county San Bernardino County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Rialto, CA
County
San Bernardino County, CA
State
California
Population B01003104,1432,197,10439,287,377
Population, 2020 census P1104,0262,181,65439,538,223
Median age B0100232.634.737.9
Under 18 B0100126.7%25.5%22.0%
65 and over B0100110.8%12.6%15.7%
Households B1100127,047674,91513,548,091
Foreign born B0500224.6%21.6%27.0%
Median household income B19013$88,857$85,478$99,122
Median family income B19113$94,417$93,416$113,346
Per capita income B19301$27,742$34,343$49,513
Poverty rate B1700112.7%13.3%12.0%
Unemployment rate B230257.7%7.1%6.6%
Civilian labor force B2302551,2321,046,62420,068,466
Mean commute (minutes) B0801331.932.628.7
Bachelor's degree or higher B1500312.6%23.3%37.1%
Housing units B2500127,973743,88614,644,735
Owner-occupied B2500366.2%62.1%55.9%
Renters B2500333.8%37.9%44.1%
Median home value B25077$487,900$505,000$734,700
Median gross rent B25064$1,759$1,801$2,036
White, not Hispanic B030028.8%24.7%33.8%
Black B0300211.3%7.5%5.2%
Hispanic or Latino B0300274.8%55.2%40.2%
Asian B030022.2%8.1%15.3%
American Indian and Alaska Native B030020.1%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rialto, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.